|
| Trials | Sample () | Male : female | Age (years) | Experimental | Control | Duration (months) | Outcomes measured |
|
| Qi et al. 2007 [11] | 42 (23/19) | 25 : 17 | 36–72 | CDDP | Vitamin B1 + LuDing tablets | 3 | Visual acuity, hemorrhage, microaneurysm |
| He and Zheng 2013 [12] | 84 (42/42) | 48 : 36 | 32–70 | CDDP | Placebo | 2 | Visual, exudate, hemorrhage,
microaneurysm |
| Xu 2011 [13] | 80 (40/40) | 39 : 41 | 52.3
54.5 | CDDP | LuDing tablets + vitamin C + PanShengDing tablets | 3 | Efficacy,
microaneurysm |
| Zhon et al. 2008 [14] | 64 (34/30) | 38 : 26 | 32–72
34–74 | CDDP | LuDing tablets + vitamin C | 3 | Efficacy,
FFA |
| Liu and Hao 2011 [15] | 52 (26/26) | 30 : 22 | 39–76 | CDDP | LuDing tablets + vitamin C + inosine tablets | 3 | Visual acuity, hemorrhage, microaneurysm |
| Meng et al. 2011 [16] | 58 (30/28) | 39 : 19 | 50.60 ± 8.70
51.20 ± 7.90 | CDDP + calcium dobesilate | Calcium dobesilate | 6 | Efficacy |
| Chen and Zhon 2006 [17] | 63 (31/32) | 32 : 31 | 54.60 ± 10.40
58.12 ± 9.31 | CDDP | Calcium dobesilate | 3 | Efficacy,
visual acuity |
| Zhou 2008 [18] | 46 (28/18) | 23:23 | 50.40 ± 8.70
50.50 ± 9.36 | CDDP | Calcium dobesilate | 6 | Efficacy |
| Wang et al. 2016 [19] | 90 (45/45) | 47 : 43 | 47–77
48–76 | CDDP | Calcium dobesilate | 2 | Efficacy,
visual acuity, FFA |
| Jin et al. 2009 [20] | 58 (30/28) | 31 : 27 | 62.78 ± 7.69
61.11 ± 7.27 | CDDP | Calcium dobesilate | 3 | Visual acuity, hemorrhage, microaneurysm |
| Shi 2010 [21] | 68 (35/33) | 36 : 32 | 38–76 | CDDP + calcium dobesilate | Calcium dobesilate | 3 | Efficacy |
| Luo et al. 2015 [22] | 57 (28/29) | 37 : 20 | 59.54 ± 7.46
57.8 ± 10.03 | CDDP | Calcium dobesilate | 3 | Visual acuity, hemorrhage,
microaneurysm |
| Lian et al. 2015 [23] | 112 (56/56) | 52 : 60 | 58.97 ± 7.6
58.97 ± 8.1 | CDDP | Placebo | 6 | Exudate, hemorrhage, FFA,
microaneurysm |
|
